Milk Fermented with Lactobacillus fermentum Ameliorates Indomethacin-Induced Intestinal Inflammation: An Exploratory Study

• Published in: Nutrients Vol. 11; no. 7; p. 1610
• Main Authors: Santiago-López, Lourdes, Hernández-Mendoza, Adrián, Vallejo-Cordoba, Belinda, Mata-Haro, Verónica, Wall-Medrano, Abraham, González-Córdova, Aarón F
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.07.2019; MDPI
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - toxicity; Antigen-presenting cells; Bacteria; Cell activation; Colon; Cytokines; Cytokines - genetics; Cytokines - metabolism; Dendritic cells; Fermentation; fermented milk; Fermented milk products; Gene Expression Regulation - drug effects; Indomethacin; Indomethacin - toxicity; Inflammation; Inflammation - chemically induced; Inflammation - therapy; Inflammatory bowel disease; Injury analysis; Intestinal Diseases - chemically induced; Intestinal Diseases - therapy; Intestine; Intestines - drug effects; Intestines - pathology; Kidney - drug effects; Kidney - pathology; Lactobacillus fermentum; Lactobacillus fermentum - physiology; Liver - drug effects; Liver - pathology; Macrophages; Mice, Inbred C57BL; Milk; Neutrophils; Organ Size; Permeability; Probiotics; Proteins; Rodents; Spleen - drug effects; Spleen - pathology; Yogurt; United States > US; Mexico; inflammation; fermented milk; indomethacin
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu11071610

The aim of this study was to evaluate the effect of milk fermented with J20 (FMJ20) or J28 (FMJ28) on ameliorating indomethacin-induced inflammation. Twenty-eight male C57Bl/6 mice were divided into four experimental groups: indomethacin, indomethacin + FMJ20, indomethacin + FMJ28, and untreated (control). Groups were fed fermented milk for 15 days, followed by administration of indomethacin supplied in three sub-doses over experimental period. Body weight, and food consumption were recorded. Additionally, spleen, kidney, and liver were weighed, and the small intestine length was measured. The cytokines in serum (IL-2, IL-4, IL-6, IL-10, IL-17, IL-23 and TNFα) and in intestinal mucosa (IL-17 and IFNγ) were also determined. Compared to the control, all indomethacin-supplemented groups lost weight (~2.7 g; < 0.05), but no changes were found in the organ-specific morphometry analysis. FMJ28 showed better results in attenuating serum and intestinal IL-17 levels. Furthermore, showed less epithelial cell loss and inflammatory infiltrates than the other indomethacin-treated groups. These results suggest that FMJ28 may be effective in reducing intestinal and systemic acute inflammation, specifically in mice.